Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02910531 · ClinicalTrials.gov registry record · Phase 2
Lipoic Acid Supplement for Cystine Stone
A Phase 2 study of Cystinuria, sponsored by Thomas Chi, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT02910531 is a Phase 2 study of Cystinuria that is active but no longer recruiting, run by Thomas Chi, MD. The registered enrollment target is 50 participants, below the 888-participant average among 4 other Cystinuria trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02910531, a Phase 2 study of Cystinuria, is active but no longer recruiting, sponsored by Thomas Chi, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates how daily alpha lipoic acid supplementation affects cystine kidney stone recurrence. Half of the subjects will receive 1200 mg alpha lipoic acid orally daily for three years, while the other half will receive a placebo. The funding source for this clinical trial is FDA OOPD.
Conditions Studied
Interventions
- DRUG Placebo
- DIETARY_SUPPLEMENT Alpha lipoic acid
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2017-06-19 |
| Est. Completion | 2025-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02910531
The ClinicalTrials.gov registry entry for NCT02910531 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 888-participant average among 4 other Cystinuria trials with a reported enrollment target (94% lower). The listed sponsor is Thomas Chi, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystinuria appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02910531 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02910531 about?
NCT02910531 is a clinical study titled "Lipoic Acid Supplement for Cystine Stone". This study evaluates how daily alpha lipoic acid supplementation affects cystine kidney stone recurrence. Half of the subjects will receive 1200 mg alpha lipoic acid orally daily for three years, while the other half will receive a placebo. The funding source for this clinical trial is FDA OOPD.
What is the current status of trial NCT02910531?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2017-06-19. Estimated completion is 2025-06.
What conditions does trial NCT02910531 study?
This clinical trial studies the following conditions: Cystinuria.
What interventions are being tested in trial NCT02910531?
The interventions under investigation include: Placebo (DRUG), Alpha lipoic acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02910531?
This trial is sponsored by Thomas Chi, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02910531 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystinuria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.